(Q73906732)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9382122%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9382122%20AND%20SRC:MED&resulttype=core&format=json

postmenopausal osteoporosis

7 November 2019

main subject

1 reference

D Thiébaud

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9382122%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

P Burckhardt

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9382122%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

H Kriegbaum

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9382122%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

H Huss

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9382122%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

H Mulder

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9382122%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

J R Juttmann

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9382122%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

K H Schöter

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9382122%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 October 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9382122%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Medicine

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9382122%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9382122%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9382122%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

298-307

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9382122%20AND%20SRC:MED&resulttype=core&format=json

Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

The prevention and treatment of osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

The role of bisphosphonates in the prevention and treatment of osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

Clinical pharmacology of alendronate sodium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

Pamidronate: an unrecognized problem in gastrointestinal tolerability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

BM 21.0955, a potent new bisphosphonate to inhibit bone resorption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

Prevention and treatment of osteoporosis: a review of current modalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

Studies of the oral bioavailability of alendronate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

Esophagitis associated with the use of alendronate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900249-0

10.1016/S0002-9343(97)00249-0

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9382122%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference